SN-38
- Generic Name
- SN-38
- Brand Names
- Trodelvy
- Drug Type
- Small Molecule
- Chemical Formula
- C22H20N2O5
- CAS Number
- 86639-52-3
- Unique Ingredient Identifier
- 0H43101T0J
- Background
7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan Irinotecan, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negat...
- Indication
Investigated for use/treatment in colorectal cancer.
- Associated Conditions
- Hormone Receptor Positive Metastatic Breast Cancer, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Triple Negative Breast Cancers, Unresectable Triple-Negative Breast Carcinoma, Metastatic HR Positive, HER2/Neu Negative Breast Cancer, Unresectable Locally Advanced Triple-negative Breast Cancer, Unresectable, locally advanced HR Positive, HER2/Neu Negative Breast Cancer, Unresectable, locally advanced Hormone Receptor Positive Breast Carcinoma
- Associated Therapies
- -
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 165
- Registration Number
- NCT03964727
- Locations
- ๐บ๐ธ
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
๐บ๐ธArizona Oncology Associates PC-HAL, Goodyear, Arizona, United States
๐ฆ๐บLyell McEwin Hospital, Elizabeth Vale, South Australia, Australia
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 543
- Registration Number
- NCT03901339
- Locations
- ๐บ๐ธ
The University of Kansas Cancer Center, Westwood, Kansas, United States
๐บ๐ธUniversity of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธMaryland Oncology Hematology, P.A., Rockville, Maryland, United States
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 645
- Registration Number
- NCT03869190
- Locations
- ๐ช๐ธ
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
๐ช๐ธHospital Clinico Universitario de Valencia, Valencia, Spain
๐จ๐ณNational Taiwan University Hospital, Yun-Lin Branch, Huwei Township, Taiwan
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 31
- Registration Number
- NCT03725761
- Locations
- ๐บ๐ธ
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Center, New York, New York, United States
๐บ๐ธWeill Cornell Medical College, New York, New York, United States
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionDrug: CarboplatinProcedure: Computed TomographyBiological: DurvalumabDrug: Gemcitabine HydrochlorideProcedure: Magnetic Resonance ImagingDrug: Nab-paclitaxelBiological: Personalized Synthetic Long Peptide VaccineDrug: Poly ICLCBiological: Sacituzumab GovitecanBiological: Tremelimumab
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT03606967
- Locations
- ๐บ๐ธ
Moffitt Cancer Center at Wesley Chapel, Wesley Chapel, Florida, United States
๐บ๐ธUC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
๐บ๐ธUniversity of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 643
- Registration Number
- NCT03547973
- Locations
- ๐บ๐ธ
The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธUniversity of California San Francisco, San Francisco, California, United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- Drug: CapecitabineDrug: AtezolizumabDrug: Ribociclib (dose #1)Drug: Inavolisib (dose #2)Drug: AbemaciclibDrug: Trastuzumab DeruxtecanDrug: IpatasertibDrug: Sacituzumab GovitecanDrug: FulvestrantDrug: Ribociclib (dose #2)Drug: Inavolisib (dose #1)Drug: SGN-LIV1ADrug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug: TocilizumabDrug: BevacizumabDrug: LetrozoleDrug: Nab-PaclitaxelDrug: InavolisibDrug: Selicrelumab
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
๐บ๐ธUniversity of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States
๐บ๐ธStanford Cancer Institute, Stanford, California, United States
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Interventions
- Drug: AtezolizumabDrug: DocetaxelDrug: RO6958688Drug: CPI-444Drug: LinagliptinDrug: Sacituzumab GovitecanDrug: BevacizumabDrug: CamonsertibDrug: CobimetinibDrug: IpatasertibDrug: PemetrexedDrug: EvolocumabDrug: TiragolumabOther: RadiationDrug: TocilizumabDrug: CarboplatinDrug: GemcitabineDrug: XL092
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 675
- Registration Number
- NCT03337698
- Locations
- ๐จ๐ณ
Taipei Veterans General Hospital, Taipei City, Taiwan
๐ช๐ธHospital Clinico Universitario de Valencia, Valencia, Spain
๐จ๐ณNational Cheng Kung University Hospital; Gasterointestinal, Tainan City, Taiwan
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 529
- Registration Number
- NCT02574455
- Locations
- ๐บ๐ธ
Southern Cancer Center, 29653 Anchor Cross Blvd, Daphne, Alabama, United States
๐บ๐ธSouther Cancer Center, 3719 Dauphin St., 5 Floor, Mobile, Alabama, United States
๐บ๐ธSouthern Cancer Center, 3 Mobile Infirmary Circle, Mobile, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.